The Need for Drug Formulation Changes in a Super-Aged Society
As Korean society rapidly transitions into a super-aged society, the demand for healthcare and medication convenience for the elderly is growing. Elderly patients with chronic diseases often need to take multiple medications, increasing their burden. To address this, the pharmaceutical industry is actively developing patient-specific drug formulations, with the 'ODDFS' platform technology gaining significant attention.
The increase in the elderly population directly correlates with a rise in chronic disease patients. As of 2023, individuals aged 65 and older account for 18.4% of the total population, with a significant portion suffering from chronic conditions like hypertension, diabetes, and osteoporosis. These patients often need to take medication multiple times a day, or struggle with swallowing large pills. Therefore, developing patient-specific formulations is essential to improve medication adherence and maximize treatment outcomes.
The Innovative Role of the 'ODDFS' Platform Technology
'ODDFS (Orally Disintegrating/Fast Dissolving Films)' is a platform technology for developing orally dissolving film formulations. This technology creates drugs in a thin film that dissolves or disperses quickly in the mouth, allowing for easy administration without water. It is particularly useful for elderly patients, children, and those who have difficulty swallowing or are reluctant to take medication.
The 'ODDFS' platform technology can dramatically improve medication convenience for patients. Unlike traditional pills or capsules that need to be swallowed with water, orally dissolving films dissolve quickly in the mouth, eliminating the need for water. This solves the problem of elderly patients struggling to find water or having difficulty swallowing. Additionally, orally dissolving films are easy to carry and administer, allowing patients to take their medication anytime, anywhere.
Adoption of 'ODDFS' Platform Technology in the Pharmaceutical Industry
Both domestic and international pharmaceutical companies are actively investing in developing various drugs using the 'ODDFS' platform technology. Orally dissolving films are being developed in various fields, including chronic disease treatments, mental illness treatments, and pain relievers. For example, some pharmaceutical companies are developing orally dissolving film formulations of Alzheimer's disease medications to help patients take their medication more easily.
“The 'ODDFS' platform technology can significantly contribute to improving medication convenience, a crucial task in an aging society. We will strive to enhance medication adherence and maximize treatment effectiveness through patient-specific formulation development.”
Furthermore, the 'ODDFS' platform technology can also improve the bioavailability of drugs. Because the drug is rapidly absorbed through the oral mucosa, it can be delivered directly into the bloodstream without passing through the liver. This can lead to faster drug effects and reduced side effects. In fact, some studies have reported that orally dissolving film formulations have higher bioavailability than traditional pills.
Future Prospects and Challenges
As the aging society deepens, the shift towards drug formulations using the 'ODDFS' platform technology is expected to accelerate. The pharmaceutical industry is likely to invest in developing more innovative formulations to meet the diverse needs of patients. Additionally, the government needs to support the development of patient-specific drugs and ease related regulations to promote innovation in the pharmaceutical industry.
“The government should actively support the development of patient-specific drugs to improve medication convenience for elderly patients. It should also ease related regulations to promote innovation in the pharmaceutical industry and ensure that patients can easily access new drug formulations.”
However, there are still challenges to overcome for the commercialization of the 'ODDFS' platform technology. For example, ensuring the stability of orally dissolving films and establishing a mass production system are crucial. Additionally, improving the taste and aroma of the drugs is necessary to ensure that patients can take them without resistance. To address these challenges, the pharmaceutical industry must continuously invest in research and development and collaborate with the government to advance related technologies. It is expected that more diverse 'ODDFS' platform technology-based drugs will be launched starting in 2024.
Patient-specific drug formulation changes are one of the critical tasks in an aging society. Through innovative formulation development using the 'ODDFS' platform technology, patients will be able to take medication more conveniently and effectively. This change is expected to improve the quality of life for patients and contribute to creating a healthy society. More detailed information can be found on the Hyunbit Media website.
“Patient-centered drug development is essential in an aging society. We will do our best to improve medication convenience and maximize treatment effectiveness for patients through innovative technologies like the 'ODDFS' platform.”